Population Pharmacokinetics of Antiretroviral in Children

NI17010HLJ

The purpose of this study is to develop population pharmacokinetic models for antiretroviral drugs in a pediatric population. The interest of these models is multiple : * describe the pharmacokinetics of these drugs in children and explain the inter-individual variability of concentrations through covariates such as weight, age, sex, smoking status, co-treatments and bilirubin; * estimate maximum, minimum and exposure concentrations from the individual pharmacokinetic parameters for each patient; * propose adaptations of doses for certain classes of children (according to age, weight etc.) and individualize the doses.

2017-06-16

2022-06-16

2022-06-16

Completed

65

Inclusion Criteria: * Children from 0 to 18 years; * Treatment with one antiretroviral drug (s) studied (dolutegravir, raltégravir, rilpivirine, nevirapine, atazanavir, darunavir, ritonavir)); * Blood dosage of the drug (s) as part of their therapeutic follow-up in the Pharmacology laboratory of the Cochin hospital between 2007 and 2017 Exclusion Criteria: * Concentration too low below the limit of quantification (indicating an absence of medication * patient with doubt about compliance

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'RETROSPECTIVE'}, 'enrollmentInfo': {'count': 65, 'type': 'ACTUAL'}}

2023-02-21